New contraceptive options.
New contraceptive modalities that are being introduced into the US marketplace reflect many changes in the delivery of existing steroidal products. These products are available now not only as oral medications but also as transdermal, intravaginal, intrauterine, and implantable or injectable devices. Each of these has its own unique profile and enhances the ability of consumers to pick and choose the product that is most acceptable to them. However, development of new barrier contraceptives, particularly those that have the potential to reduce the heterosexual transmission of HIV or to reduce a bacterial infection such as Chlamydia or Neisseria gonorrhea, continues to be moving forward in clinical trials. These products can have a lower efficacy compared with the steroidal products but, because of their other benefits, may be of significant medical use.
Archer
D F
DF
Department of Obstetrics and Gynecology, Jones Institute of Reproductive Medicine, 601 Colley Avenue, Norfolk, VA 23507, USA.
D002755:Choice Behavior; D017280:Condoms / Q000600:supply & distribution; D003267:Contraception / Q000295:instrumentation / Q000379:methods* / Q000523:psychology / Q000639:trends; D003270:Contraceptive Agents / Q000600:supply & distribution; D003274:Contraceptive Devices, Female / Q000600:supply & distribution; D004343:Drug Implants; D005260:Female; D006801:Humans; D007434:Intrauterine Devices / Q000600:supply & distribution; D008297:Male; D008389:Marketing of Health Services; D018579:Patient Selection; D013089:Spermatocidal Agents / Q000600:supply & distribution; D014481:United States
D003270:Contraceptive Agents; D004343:Drug Implants; D013089:Spermatocidal Agents